Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy

• Status: Recruiting
• Trial end date: 2026-04-29
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this single arm, phase Ⅱ clinical trial is to evaluate the efficacy and safety of Anlotinib Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma after failure of no less than second-line chemotherapy or targeted therapy

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University

Criteria

Inclusion Criteria:

• biopsy proved nasopharyngeal carcinoma;

• stage IVB according to American Joint Committee on Cancer(AJCC) edition VIII, or recurrent disease after chemotherapy and/or radiotherapy;

• 18 years or older; without other malignancy;

• proper functioning of the major organs.

Exclusion Criteria:

• allergic to anlotinib;

• female within gestation period or lactation;

• patients received drug of other clinical trial within 4 weeks.